Primary bony and cartilaginous sarcomas of chest wall: Results of therapy Journal Article


Authors: Burt, M.; Fulton, M.; Wessner-Dunlap, S.; Karpeh, M.; Huvos, A. G.; Bains, M. S.; Martini, N.; McCormack, P. M.; Rusch, V. W.; Ginsberg, R. J.
Article Title: Primary bony and cartilaginous sarcomas of chest wall: Results of therapy
Abstract: Primary bony and cartilaginous sarcomas of the chest wall are uncommon, and data concerning treatment and results are sparse. To assess the results of therapy, we reviewed our 40-year experience. Records of 38 patients with osteosarcoma and 88 with chondrosarcoma arising in chest wall admitted to Memorial Sloan-Kettering Cancer Center from 1949 to 1989 were reviewed. The 88 patients with condrosarcoma ranged in age from 5 to 86 years (median age, 49 years); the male/female ratio was 1.3:1. Presenting complaint was mass, pain, or both in 93%. Primary therapy was resection (n = 84), radiation therapy (n = 3), or chemotherapy (n = 1). Overall 5-year survival was 64%. Significant adverse prognostic factors included metastases at initial presentation (n = 9), metastases at any time during the course of disease (n = 23), age greater than 50 years (n = 42), incomplete or no resection (n = 13), and local recurrence (n = 24). Sex, grade, and tumor size were not prognostic factors. The 38 patients with osteosarcoma ranged in age from 11 to 78 years (median age, 42 years); the male/female ratio was 1.5:1. Presenting complaint was mass, pain, or both in 95%. Primary therapy included resection (n = 31; alone in 13, with radiation therapy in 3, with chemotherapy in 15), radiation therapy (n = 3), radiation therapy and chemotherapy (n = 2), chemotherapy (n = 1), or no treatment (n = 1). Overall 5-year survival was 15%. Significant adverse prognostic factors included presence of synchronous metastases (n = 13) and metastases at any time during the course of disease (n = 26). Age, sex, tumor size, local recurrence, and extent of resection were not prognostic factors. In conclusion, patients with chest wall osteosarcoma have a significantly decreased 5-year survival (15%) compared with those with chondrosarcoma (64%). Resection allows acceptable survival for patients with chondrosarcoma, but the role of adjuvant therapy should continue to be explored in patients with osteosarcoma of chest wall.
Keywords: osteosarcoma; chemotherapy; tumors; experience; chondrosarcoma; management; adjuvant; preoperative chemotherapy; factors affecting survival
Journal Title: Annals of Thoracic Surgery
Volume: 54
Issue: 2
ISSN: 0003-4975
Publisher: Elsevier Science, Inc.  
Date Published: 1992-08-01
Start Page: 226
End Page: 232
Language: English
ACCESSION: WOS:A1992JF48600006
DOI: 10.1016/0003-4975(92)91374-i
PROVIDER: wos
PUBMED: 1637209
Notes: Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Valerie W Rusch
    865 Rusch
  2. Robert J Ginsberg
    178 Ginsberg
  3. Martin S Karpeh
    98 Karpeh
  4. Manjit S Bains
    338 Bains
  5. Andrew G Huvos
    289 Huvos
  6. Nael   Martini
    105 Martini
  7. Michael E. Burt
    187 Burt